MRIKPA – MRI KPA https://mrikpa.org.uk Local support for Kidney Patients across the North West Wed, 12 Aug 2026 14:19:33 +0000 en-GB hourly 1 https://wordpress.org/?v=7.1 https://mrikpa.org.uk/wp-content/uploads/2024/04/MRIKPA-Logo-250x250-Orange-150x150.webp MRIKPA – MRI KPA https://mrikpa.org.uk 32 32 August 13th Park Walk Cancelled https://mrikpa.org.uk/august-13th-park-walk-cancelled/ https://mrikpa.org.uk/august-13th-park-walk-cancelled/#respond Wed, 12 Aug 2026 14:19:33 +0000 https://mrikpa.org.uk/?p=5160
AUGUST 13TH PARK WALK CANCELLED
Unfortunately, due to the extremely high temperatures forecast during Thursday’s planned August Park Walk, we have decided it most suitable to cancel this month’s walk.
Please join our WhatsApp Group Chat – link on our Park Walk webpage for any additional details and a possible online alternative meet-up….or to look ahead to our September 17th Park Walk.
Join our WhatsApp Chat Group – visit the Park Walk Page for the link: https://mrikpa.org.uk/casual-park-walks/
]]>
https://mrikpa.org.uk/august-13th-park-walk-cancelled/feed/ 0
MRIKPA AGM 2025/26: join us on Sunday 13 September https://mrikpa.org.uk/mrikpa-agm-2026/ https://mrikpa.org.uk/mrikpa-agm-2026/#respond Tue, 11 Aug 2026 14:02:03 +0000 https://mrikpa.org.uk/?p=5133 Our Annual General Meeting is one of the most important dates in the MRIKPA calendar, and this year you are warmly invited to join us. The MRIKPA AGM 2025/26  is your chance to hear about the work we have been doing, to meet the people behind the association, and to ask us anything you like about your care and our plans for the year ahead.

As a volunteer, patient-run charity that works alongside the renal service at Manchester Royal Infirmary, we exist to help kidney patients get the best care possible. The AGM is where our members help shape what we do next, so your voice really does matter. You can always find the latest information on our AGM page.

When and where the MRIKPA AGM 2025/26 takes place

This year the meeting will be a hybrid event, so you are welcome to come along in person or to join us online via Zoom, whichever suits you best.

  • Date: Sunday 13 September 2026
  • Time: 10:00am
  • In person: Smart Cookie Tuition Centre, 142A Moss Lane, Hale, Altrincham, WA15 8AN
  • Online: via Zoom, using the joining details below

Joining the AGM online via Zoom

  • Zoom Meeting ID: 869 1134 4510
  • Passcode: 797374

The Zoom link will be live from 9.50am. Please do not try to log in before then. If you would like the Zoom link emailed to you, or you have any other questions, simply email us at support@mrikpa.org.uk and we will be glad to help.

Meeting papers and agenda

Copies of the draft minutes of the 2025 AGM, this year’s agenda and the Chair’s Report will be available from our AGM page from 13 September. You are welcome to visit that page at any time for the latest details.

The AGM is one of the best chances we get to sit down together as a community and share what we have achieved over the year. Whether you have been a member for decades or you are only just finding us, you are very welcome. Come along, have a cup of tea with us, and tell us how we can help.

, Guy Hill, Chair of MRIKPA

If you cannot make the AGM but would still like to stay involved, we would love to see you at one of our casual park walks, or you can find out more about becoming a member. However you choose to take part, thank you for being part of the MRIKPA community. For full joining details please see our AGM page, and if you know a member who is not online, please do pass this information on to them.


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/mrikpa-agm-2026/feed/ 0
Kidney transplant support: the team that helps you through https://mrikpa.org.uk/kidney-transplant-support-team/ https://mrikpa.org.uk/kidney-transplant-support-team/#respond Tue, 11 Aug 2026 13:59:50 +0000 https://mrikpa.org.uk/?p=5082 If you or someone you love is working towards a kidney transplant, you will know it is a journey with many steps, not a single moment in an operating theatre. Good kidney transplant support can make that journey feel steadier, and it comes from far more than the surgical team alone. A recent article has been a welcome reminder of just how much the people around a patient shape the outcome.

More than an operation

Reaching a transplant, and doing well afterwards, involves preparation, waiting and careful aftercare. Patients need to take in a good deal of health information, get through assessments, and then, once transplanted, settle into a new routine of medication and check-ups. Strong kidney transplant support helps at every one of these stages, turning a daunting process into a series of manageable steps. For many people, understanding what lies ahead is itself a source of reassurance, and you can read more about what to expect in our guide to understanding the patient journey.

The people behind good kidney transplant support

In the NHS, a kidney transplant is looked after by a whole team, not one clinician. Alongside surgeons and nephrologists, renal social workers, transplant coordinators, specialist nurses, dietitians and psychologists all play a part. They help patients navigate the system, work through practical obstacles such as transport or time off work, and talk honestly about the worries that naturally come with waiting. This quieter side of care is one of the most valuable parts of the whole picture, and it is a feature of the teams here in Greater Manchester too. You can learn more about renal care at Manchester Royal Infirmary on our website.

Small barriers, big difference

Some of the things that can hold people back from transplant are what clinicians call modifiable, meaning they can be worked on with the right help. Reaching a healthier weight, stopping smoking, or simply feeling confident enough to ask questions can all improve a person’s chances. Practical and emotional kidney transplant support, whether from a renal social worker or from family at home, often makes these changes feel possible rather than overwhelming. Families and carers carry a great deal too, and we have gathered some helpful resources for carers for exactly this reason.

Support that lasts beyond the operation

Care does not stop at discharge. Keeping to immunosuppressant medication, attending clinics and looking after general health all help a new kidney last as long as possible. People who feel well informed and well supported tend to manage this aftercare more confidently, which is good for them and good for the kidney they have been given. Ongoing kidney transplant support, then, is not a nice extra. It is part of what helps a transplant succeed for the long term.

Source: “Beyond the Clinical: How Social Workers Drive Kidney Transplant Success”, DaVita Newsroom (United States), 21 May 2026. The original describes the US care setting. Here we reflect on what good kidney transplant support looks like for patients in the UK. Read the original article here.

At MRIKPA, we welcome any reminder that a kidney transplant is a team effort, and that the human support around a patient matters just as much as the clinical care. We are a small, patient-run community based at Manchester Royal Infirmary, and we know from our own lives how much a friendly, understanding voice can help. You can follow more stories like this on our research and news pages, and if you would value connecting with others who understand this journey from the inside, you are always welcome to get in touch with us at support@mrikpa.org.uk or on 07745 242 684.


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/kidney-transplant-support-team/feed/ 0
New Funding Brings Fresh Hope for Polycystic Kidney Disease Treatment https://mrikpa.org.uk/polycystic-kidney-disease-treatment-funding-2026/ https://mrikpa.org.uk/polycystic-kidney-disease-treatment-funding-2026/#respond Tue, 04 Aug 2026 09:58:54 +0000 https://mrikpa.org.uk/?p=5079 Living with a hereditary kidney condition often means holding two things at once, getting on with everyday life while keeping half an eye on what research might bring next. For anyone affected by polycystic kidney disease, news of fresh investment in new treatments is exactly the kind of hope worth holding onto. This month brought a genuine step forward from right here in the UK.

A Glasgow biopharmaceutical company, Mironid, has raised £34 million to advance a new treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The funding round included an £8.4 million investment from the Scottish National Investment Bank, which joined existing backers including the Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde. The money will support the clinical development of Mironid’s treatment, moving it closer to the patients who need it.

Why polycystic kidney disease matters to our community

ADPKD is the most common inherited kidney disorder. According to Mironid, it affects more than 12 million people worldwide, and around half of those living with it will develop kidney failure by the age of 60. Because it is passed down through families, many of our members know it not as a single diagnosis but as something that has touched parents, siblings and children too. That is why research into treatments that could slow the disease feels so personal for so many kidney families.

Mironid’s approach uses small molecule therapies designed to target the specific biological processes that drive the growth of cysts on the kidneys. The company, which grew out of collaboration between the University of Strathclyde and Heriot-Watt University, has been developing this work over several years. We have written before about other promising avenues in this area, including a new antibody therapy for polycystic kidney disease, and it is encouraging to see more than one line of research now gathering pace.

A vote of confidence in kidney science

What makes this announcement stand out is not only the size of the sum but who is behind it. Neil Wilkie, the chief executive of Mironid, described the backing from such an experienced group of investors as a strong endorsement of the company’s approach to treating rare kidney diseases. Paul Callaghan, a director at the Scottish National Investment Bank, said the investment reflected a commitment to backing Scottish innovation that could improve options for people living with kidney disease.

For those of us who follow this field closely, that kind of investor confidence matters. Developing a new medicine is long and costly, and funding at this stage is often what carries promising science from the laboratory towards clinical trials and, eventually, the clinic. It is a reminder that world-class kidney research is happening within the UK, not only overseas.

What this means for patients today

It is worth being honest about timescales. This is early clinical development, and a treatment reaching this milestone is not the same as a treatment available on prescription. There is still a long road of trials and regulatory review ahead before anything could reach NHS patients. Even so, every step like this widens the horizon for people whose options today can feel limited.

At MRIKPA, we are always heartened when research that could make a real difference to kidney patients gains the support it needs to move forward. As Guy Hill, Chair of MRIKPA, puts it: “Developments like this remind us why it is so important to keep following the science and sharing what we learn with our members. It gives our community genuine reasons for hope, even while we know there is still work to do before it reaches people day to day.” You can keep up with stories like this on our research and news pages.

Source: “Biopharma firm Mironid raises fund for kidney treatment”, Daily Business, 5 August 2026. Read the original report here.

If you or someone in your family lives with polycystic kidney disease and you would value speaking with others who understand from the inside, you are always welcome to reach out. We are a small, patient-run community based at Manchester Royal Infirmary, and you can find more guidance in our Patient Knowledge Bank or get in touch with us at support@mrikpa.org.uk or on 07745 242 684.


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/polycystic-kidney-disease-treatment-funding-2026/feed/ 0
South Asian organ donation: why the conversation matters https://mrikpa.org.uk/south-asian-organ-donation/ https://mrikpa.org.uk/south-asian-organ-donation/#respond Sun, 02 Aug 2026 18:35:10 +0000 https://mrikpa.org.uk/?p=5139 For many kidney patients, a transplant is the hope that keeps us going. Yet new NHS figures show that hope can take far longer to arrive for some of us than others, and South Asian organ donation is at the heart of the problem. Behind the numbers are families making generous, difficult decisions, and communities beginning to talk more openly about donation.

Organs are matched by blood and tissue type, so the closest match for a patient often comes from a donor of similar heritage. When there are too few donors from a particular background, patients from that background wait longer. It is a quiet inequality that many of our members will recognise.

What the NHS figures show about South Asian organ donation

According to NHS Blood and Transplant, just 26 deceased donors of South Asian heritage were recorded between April 2025 and March 2026, while 554 patients of the same heritage were waiting for a transplant. That is more than 20 times as many people waiting as there were donors. The figures also show that adults of Asian heritage wait an average of 648 days for a kidney, against a UK average of 547 days. For children of Asian heritage the average wait is 709 days, compared with 450 days across the UK.

The wider picture is stark. A record of more than 8,500 people are now on the UK transplant waiting list. In March 2026, patients of South Asian heritage made up 90.1 per cent of those listed for a kidney, against 86.4 per cent of the list overall. NHS Blood and Transplant notes that people of South Asian heritage are more likely to develop diabetes and high blood pressure, both of which can damage the kidneys.

Why the waits are longer

Part of the South Asian organ donation shortfall comes down to biology. Harpreet Matharu, a regional head of nursing at NHS Blood and Transplant, has explained that a shortage of close genetic matches makes long waits more likely, and that sadly some people waiting for a transplant will never receive one. She stressed how important it is to record your decision on the NHS Organ Donor Register, so that families can be certain of your wishes. Last year, according to the figures, 67 per cent of Asian heritage families agreed to donation where the person had already joined the register, compared with 85 per cent among all other ethnic groups. Confirming your decision, and telling your family, makes a real difference.

One family who chose to help others

The BBC report told the story of Sunni Bansal, who died suddenly in February at the age of 34. His mother, Bevi Sandhu, 55, from Hounslow in west London, agreed to donate his organs. His kidneys went to two men and his heart to a man of 30, and his family later learned that his donation had helped save three lives. Bevi has spoken about how donation felt like a way for a caring young man to go on helping others, and how having a letter about the donation read aloud at his Sikh funeral got friends and family talking about a subject their community rarely discusses. Her point was a simple one, that a single conversation can spark another.

Others in the community are adding their voices. Mehreen Ahmed, 25, who received a heart transplant three years ago, has said she had never heard of organ donation before she was placed on the waiting list, and would like to see more people from South Asian backgrounds start that conversation. During July, to mark South Asian Heritage Month, NHS Blood and Transplant encouraged more open conversation about South Asian organ donation and asked people to confirm their decision on the register. You can read more about the specific issues affecting South Asian and other communities and organ donation on our website, and find out how to register your own decision.

At MRIKPA, we know that conversations about donation are not always easy, and that for grieving families they come at the hardest of times. We are grateful to families like the Bansals who choose to help others, and we gently encourage everyone in our community, whatever their background, to think about organ donation and to make their wishes known. It is one of the most powerful things any of us can do for a fellow patient. You can follow more stories like this on our research and news pages.

Source: “South Asian donor shortage leaves long organ waits”, BBC News (Adriana Elgueta, BBC London), 27 July 2026. Read the original report here.

If you or someone close to you is living with kidney disease and you would value speaking with others who understand from the inside, you are always welcome to reach out. We are a small, patient-run community based at Manchester Royal Infirmary, and you can get in touch with us at support@mrikpa.org.uk or on 07745 242 684.


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/south-asian-organ-donation/feed/ 0
Kidney Transplant Drug Tegoprubart: What the Latest BESTOW Results Could Mean https://mrikpa.org.uk/kidney-transplant-drug-bestow-results-2026/ https://mrikpa.org.uk/kidney-transplant-drug-bestow-results-2026/#respond Thu, 09 Jul 2026 09:15:00 +0000 https://mrikpa.org.uk/?p=5036 Life after a kidney transplant often settles into a quiet daily routine built around anti-rejection medication. For most people that means Tacrolimus, a tablet taken every day that protects the new kidney but can bring side effects such as tremor, an upset stomach and low mood. So news of a possible alternative kidney transplant drug is something our community tends to watch closely, and the latest results are worth sharing.

What did the Phase 2 BESTOW trial find?

According to an announcement from Eledon Pharmaceuticals, the company developing the treatment, long-term results from its Phase 2 BESTOW programme were presented at the American Transplant Congress in Boston in June 2026.

The trial compared Tegoprubart, an experimental antibody given by infusion, against Tacrolimus, the anti-rejection tablet most transplant patients in the UK take every day. It builds on earlier work on new therapies against transplant rejection that we have followed.

The headline findings were encouraging. Kidney function, measured by a blood test called the eGFR, settled after the first month and stayed higher in the Tegoprubart group throughout. At 18 months the difference was around 12 points in the drug’s favour, a gap the researchers reported as statistically significant. No rejection episodes were seen in Tegoprubart-treated patients after the first six months, while a small number continued to occur in the Tacrolimus group. Patients on Tegoprubart also reported a lighter burden of troublesome symptoms on two validated quality-of-life questionnaires at the one-year mark, and fewer side effects such as headache, diarrhoea and falls.

This article draws on an announcement from Eledon Pharmaceuticals (22 June 2026), reporting Phase 2 BESTOW extension data presented at the American Transplant Congress. You can read the original release here.

Why a new kidney transplant drug matters for patients

For anyone living with a transplant, success is about far more than avoiding rejection. It is also about protecting kidney function for as long as possible and feeling well enough to get on with daily life. Professor Andrew Adams, a transplant surgeon at the University of Minnesota who presented the findings, described a genuinely effective alternative to Tacrolimus as one of the biggest gaps still to be filled in transplant care, precisely because lifelong immunosuppression shapes both how long a transplant lasts and how patients feel day to day. That is why a kidney transplant drug that appears to preserve function while easing side effects is such a hopeful prospect, and it sits alongside other recent research into new transplant medication we have shared. Here in Manchester, questions about anti-rejection medicines are ones the renal team at Manchester Royal Infirmary knows well.

Promising, but still an experimental treatment

It is worth staying grounded about the stage this work has reached. BESTOW is a Phase 2 trial with a relatively small number of patients, carried out mainly in the United States, and Tegoprubart is not yet approved or available anywhere. Tacrolimus remains the standard of care for transplant patients in the UK. Following a successful meeting with the American regulator, Eledon plans to begin a larger Phase 3 trial in late 2026 to test whether the drug is at least as good as Tacrolimus at preventing rejection, graft loss and death over a year. If those results hold up, it could still be some years before this kidney transplant drug reaches patients. Anyone currently on Tacrolimus should keep taking it as prescribed and speak to their renal team before making any changes.

Research like this gives our community real reasons for hope. Many of our members know the daily reality of anti-rejection medication, so anything that could protect a transplant while making people feel better day to day is something we will always keep an eye on.

Guy Hill, Chair of MRIKPA

At MRIKPA we follow transplant research closely, because so many people in our community are living with a kidney transplant or waiting for one. We will keep sharing what we learn as this wider wave of new kidney treatments develops and the larger trials take shape.

We are a small community of patients who understand this journey from the inside. If you would like to connect with others who truly get it, you are always welcome to reach out at support@mrikpa.org.uk or call 07745 242 684.

Source: Eledon Pharmaceuticals, 22 June 2026. Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress. https://ir.eledon.com/news-releases/news-release-details/eledon-presents-long-term-extension-phase-2-bestow-results


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/kidney-transplant-drug-bestow-results-2026/feed/ 0
Kidney Health: What the New NHS Walking Scheme Could Mean for Patients https://mrikpa.org.uk/nhs-walking-scheme-kidney-health-2026/ https://mrikpa.org.uk/nhs-walking-scheme-kidney-health-2026/#respond Thu, 09 Jul 2026 08:30:00 +0000 https://mrikpa.org.uk/?p=5032 When you are living with kidney disease, staying active can feel like a tall order. Fatigue, dialysis days and the ups and downs of treatment all get in the way, and a brisk daily walk is not always as simple as it sounds. So a new national push to get more of us moving is worth a closer look, especially for what it might mean for kidney health.

What is the NHS ‘marathon a month’ walking scheme?

According to the BBC, NHS England plans to launch a “marathon a month” challenge early next year, encouraging people to walk for around 30 minutes a day. Walk every day and you cover roughly 26 miles across the month, the distance of a marathon. People will be able to log their walks online or through a phone or smartwatch, and those who complete the challenge will be eligible for rewards such as discounts and other incentives. The scheme has been developed with the former Olympic medallist Sir Brendan Foster, founder of the Great North Run, as part of the 10-year health plan for England.

The thinking behind it is sobering. NHS England links physical inactivity to around one in six deaths, and a Sport England survey suggested that in the year to November 2025 nearly a quarter of adults, about 12 million people, were not active enough. Organisers hope to sign up more than 100,000 people, and to borrow the “streak” habit made familiar by apps such as Duolingo to help people keep going day after day.

This article draws on BBC News coverage (published 2 July 2026) of NHS England’s planned walking scheme. You can read the original report here.

What a daily walk can mean for kidney health

Gentle, regular movement is something many renal teams actively encourage. For a lot of people living with chronic kidney disease, walking can help with blood pressure, heart health, sleep, mood and maintaining a healthy weight, all of which matter a great deal for kidney health. It costs nothing, needs no special kit and can be built into an ordinary day. Sir Brendan Foster suggested that walking for 30 minutes five times a week could add up to four extra years of healthy life. Every patient is different, of course, but the wider message that small amounts of activity add up is a welcome one, and our healthy living tips for patients are a good place to start.

Here in Manchester, walking together is already part of MRIKPA life. Our Greater Manchester park walks show how a slow stroll in good company can be as much about connection and friendship as it is about exercise.

Building up gently, and always with your renal team

A word of realism is needed too. The scheme is still being finalised, it is focused on England, it will not begin until next year, and the organisers have not yet confirmed exactly what the rewards will be. More importantly, a “marathon a month” can sound daunting when kidney disease already takes so much of your energy. Dialysis fatigue, recovery after a transplant and other health conditions all mean that what suits one patient may be too much for another. The safest approach is to build up slowly and to check with your doctor or renal team before increasing your activity, so that any new routine genuinely supports your kidney health rather than leaving you depleted. Health experts have also cautioned that encouraging people to move more, while helpful, cannot on its own fix the nation’s health without stronger prevention measures alongside it.

We have always known how much a simple walk can lift the spirits, especially on the harder days. Anything that encourages our community to keep moving, at their own pace and within their own limits, is something we warmly welcome.

Guy Hill, Chair of MRIKPA

At MRIKPA we see the value of gentle activity every week, and if a national scheme helps more people discover it, all the better. In the meantime you are warmly invited to join our Casual Park Walks, where the pace is easy and nobody is counting the miles.

We are a small community of patients who understand this journey from the inside. If you would like to walk alongside us, or simply talk things through, you are always welcome to reach out at support@mrikpa.org.uk or call 07745 242 684.

Source: BBC News, 2 July 2026. NHS to reward people who walk 30 minutes a day. https://www.bbc.co.uk/news/articles/cj6g0rdy40jo


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/nhs-walking-scheme-kidney-health-2026/feed/ 0
Childhood Kidney Disease: What a Major New Study Means for Families https://mrikpa.org.uk/childhood-kidney-disease-spina-bifida-2026/ https://mrikpa.org.uk/childhood-kidney-disease-spina-bifida-2026/#respond Wed, 08 Jul 2026 14:03:01 +0000 https://mrikpa.org.uk/?p=5069 For many families, childhood kidney disease is something they learn to watch for quietly, through regular checks, appointments and the small changes that can matter over time. When that watchfulness begins early in a child’s life it can feel like a great deal to carry, yet it is also where some of the most reassuring progress is being made. A major new study helps explain why noticing kidney problems early can make such a real difference.

Researchers in Canada have published one of the largest studies yet to look at how often, and how early, kidney problems develop in children born with spina bifida. The work was carried out in Ontario and led by a team at the University of Toronto, and it followed millions of children over three decades. It adds real depth to what we understand about chronic kidney disease and how it is detected and treated across a lifetime.

What the Canadian study found

Published in the journal JAMA Network Open in June 2026, the study drew on health records for more than 4.3 million children born in Ontario between 1992 and 2023, including 12,868 who were living with spina bifida. According to the researchers, children with spina bifida developed chronic kidney disease at a rate of 2.7 per 1,000 person years, compared with 0.3 per 1,000 among the wider group of children. The gap for the most advanced kidney failure, known as end stage renal disease, was wider still. Put simply, childhood kidney disease was many times more common in this group.

Why kidney problems can begin so early

The study also found that kidney problems tended to appear at a younger age. The researchers reported that children with spina bifida were diagnosed with chronic kidney disease at around 5 years of age on average, compared with about 10 years in other children, and reached advanced kidney failure some years earlier too. A number of factors were linked to higher risk, including diabetes, urinary tract stones, repeated complex urinary infections and previous urological surgery. Understanding these patterns is part of the wider kidney research that helps clinicians know when to look more closely.

This article draws on a study published in JAMA Network Open on 26 June 2026, led by researchers at the University of Toronto and ICES in Ontario, Canada. You can read the original research here.

What childhood kidney disease means for families here

It is worth being clear that this research was carried out in Canada, and it looks specifically at children with spina bifida rather than every child. Even so, the message it carries travels well. Spina bifida can affect how the bladder empties, which over time can place strain on the kidneys, so careful monitoring from an early age gives the best chance of protecting kidney function. In the UK, children and adults with spina bifida are usually followed by kidney and urology teams for exactly this reason. Anyone who wants to understand more about how the kidneys work and what can affect them can find clear, patient friendly information to talk through with their own team.

At MRIKPA we welcome research that helps families and clinicians spot kidney problems sooner, because early awareness is one of the most powerful tools any of us has. This is a study from Canada, but the reminder it offers, that childhood kidney disease deserves gentle and ongoing attention, is one that resonates with our community here in the UK.

We are a small community of patients and families who understand this journey from the inside. If it would help to talk with others who truly get it, you are always welcome to reach out at support@mrikpa.org.uk or call 07745 242 684.

Source: Thomas HS and colleagues, Kidney Morbidity in Pediatric Patients With Spina Bifida, JAMA Network Open, 26 June 2026. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850844


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/childhood-kidney-disease-spina-bifida-2026/feed/ 0
World Kidney Cancer Day 2026: Know the Signs, Find Support https://mrikpa.org.uk/world-kidney-cancer-day-2026-signs-support/ https://mrikpa.org.uk/world-kidney-cancer-day-2026-signs-support/#respond Thu, 18 Jun 2026 07:00:14 +0000 https://mrikpa.org.uk/?p=4947 Thursday 18 June 2026 is World Kidney Cancer Day, a global moment led by the International Kidney Cancer Coalition, and this year marks its tenth anniversary. It is a day for raising awareness, sharing reliable information, and reminding anyone affected by kidney cancer that they are not alone. We wanted to mark it by sharing the signs worth knowing and where to turn for trusted support.

What kidney cancer is

Kidney cancer is one of the more common cancers in the UK, and like many cancers it is most treatable when it is found early. It often causes no symptoms at all in its early stages and is frequently picked up by chance during tests for something else. That is part of why awareness days like this one matter, because knowing what to look for can help people raise concerns sooner.

Signs and symptoms of kidney cancer

According to the NHS, many people with kidney cancer have no obvious symptoms. When symptoms do appear, they can include:

  • blood in your pee
  • a lump or swelling in your back, under your ribs, or in your neck
  • a pain between your ribs and waist that does not go away
  • losing weight without trying to, or a loss of appetite
  • feeling tired or having no energy
  • a high temperature, or heavy sweating including at night

It is important to remember that these symptoms are common and are far more often caused by something other than cancer. Having them does not mean you have kidney cancer, but it is always worth getting them checked.

When to see your GP

The NHS advises seeing a GP if you notice blood in your pee, a lump or swelling, or a pain in your back or side that does not go away. You should ask for an urgent appointment, or contact NHS 111, if your pee has blood in it or it becomes painful or much more frequent. Finding kidney cancer early really can make a difference to how treatable it is, so please do not put off that conversation.

This year’s focus: emotional wellbeing

The theme for World Kidney Cancer Day 2026 is kidney cancer and emotional wellbeing. The International Kidney Cancer Coalition reports that, in its 2025 global patient survey, 85% of kidney cancer patients said they had experienced emotional challenges, yet many never raised this with their care team. A diagnosis affects far more than the body, and asking for emotional support is a sign of strength, not weakness. If you are struggling, your team would far rather know.

#WorldKidneyCancerDay

Download the World Kidney Cancer Day info sheet HERE

Where to find support

You do not have to face kidney cancer, or the worry of it, on your own. The NHS has clear information on diagnosis and treatment, Kidney Cancer UK offers a support line, counselling and financial advice, and Macmillan Cancer Support provides wide-ranging help for anyone living with cancer. You can read more about the global campaign at worldkidneycancerday.org. For more patient-written information, visit our Patient Knowledge Bank and our research and news pages.

Awareness days like this one are quietly powerful. Knowing the signs, and feeling able to speak up, can change the course of someone’s health. This World Kidney Cancer Day we want people to know both the symptoms to watch for and that support is always there, for the worry as much as the diagnosis.

Guy Hill, Chair of MRIKPA

If today has raised questions or worries for you, please speak to your GP or renal team, who are the right people to advise on your own health. And if you would simply like to talk to others who understand life with kidney disease, you are always welcome to reach out to us at support@mrikpa.org.uk or on 07745 242 684.

Sources: NHS, Symptoms of kidney cancer (nhs.uk); International Kidney Cancer Coalition, World Kidney Cancer Day 2026 (ikcc.org). World Kidney Cancer Day takes place on 18 June 2026.


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/world-kidney-cancer-day-2026-signs-support/feed/ 0
A new blood pressure drug wins US approval: what it could mean for kidney patients https://mrikpa.org.uk/blood-pressure-drug-kidney-patients-2026/ https://mrikpa.org.uk/blood-pressure-drug-kidney-patients-2026/#respond Wed, 17 Jun 2026 16:45:45 +0000 https://mrikpa.org.uk/?p=4997 For many people living with kidney disease, keeping blood pressure under control is one of the most important parts of daily care, and one of the most frustrating when the numbers stay stubbornly high. So it is encouraging to see fresh progress here. A new blood pressure drug called Baxdrostat has just gained approval in the United States for people whose blood pressure stays high despite existing treatment, as reported in the journal Nature Reviews Drug Discovery.

A first of its kind blood pressure drug

Baxdrostat, which will be sold as Baxfendy, has been approved by the United States Food and Drug Administration for use alongside other blood pressure medicines. Made by AstraZeneca, it is the first of a new class known as aldosterone synthase inhibitors. Aldosterone is a hormone that helps regulate blood pressure, and this blood pressure drug works by lowering the amount the body produces. Earlier medicines aimed at this hormone also affected cortisol, a related hormone, so Baxdrostat was designed to act more selectively.

What the BaxHTN trial showed

Approval was based on a trial called BaxHTN, which involved around 800 people whose blood pressure remained high despite existing treatment, described in the trial as uncontrolled or resistant hypertension. They received Baxdrostat or a placebo in addition to their usual treatment. After 12 weeks, average seated systolic blood pressure, the top number in a reading, fell by about 14.5 points on the lower dose and 15.7 points on the higher dose, compared with about 5.8 points on placebo. Around 40 per cent of those taking the medicine reached a controlled blood pressure, against 19 per cent on placebo. The results appeared in the New England Journal of Medicine, alongside an independent editorial that welcomed the findings while noting that longer term data is still needed. One of that editorial’s authors, Professor Maciej Tomaszewski, is a hypertension specialist at the University of Manchester and Manchester Royal Infirmary, the hospital where MRIKPA was founded.

Why blood pressure matters so much for kidney health

High blood pressure and kidney disease are closely linked. Raised blood pressure can gradually damage the small blood vessels in the kidneys, and damaged kidneys can in turn push blood pressure higher, creating a difficult cycle. Bringing blood pressure down is one of the most effective ways to protect kidney function, which is why blood pressure guidance for kidney patients is such a regular part of renal care. Everyday steps matter too, and many people find approaches such as the DASH diet helpful alongside their medicines. Encouragingly, Baxdrostat is also being studied specifically in people with chronic kidney disease, so its relevance to kidney patients may grow.

What this means for patients in the UK

This approval applies in the United States. In the UK, new medicines follow their own separate route: they are first reviewed by the medicines regulator, the MHRA, and then assessed by bodies such as NICE before being offered routinely on the NHS. That process runs on its own timeline. For now, Baxdrostat is not yet available in the UK, and anyone with questions about their own blood pressure should speak with their renal or GP team about the options available to them.

At MRIKPA, we welcome developments like this that aim to give people more ways to manage a condition so central to kidney health. We will keep following Baxdrostat’s progress, including any steps towards its availability in the UK. Sometimes it simply helps to talk with people who understand from their own experience, so if you would like to connect with others, you are always welcome to get in touch at support@mrikpa.org.uk or call 07745 242 684. You can also explore more in our Patient Knowledge Bank.

Source: Asher Mullard, “FDA approves first-in-class hypertension drug”, Nature Reviews Drug Discovery, 20 May 2026. Read the original article.


This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice. Please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.

]]>
https://mrikpa.org.uk/blood-pressure-drug-kidney-patients-2026/feed/ 0